Joseph Sparano

Trials

Studies that name Joseph Sparano as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:07 UTC. Open this list on ClinicalTrials.gov

• Early Ph1
  NCT06637306 · Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

  Rima Patel · recruiting · Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer · principal investigator
• Ph1/Ph2
  NCT03709446 · Leflunomide in Previously Treated Metastatic Triple Negative Cancers

  Joseph Sparano · completed · Breast Neoplasms, Breast Diseases, Metastatic Triple Negative Breast Cancer · principal investigator
• Ph1/Ph2
  NCT01697293 · PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

  Prescient Therapeutics, Ltd. · terminated · Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative · principal investigator
• Ph1/Ph2
  NCT00574587 · Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

  Albert Einstein College of Medicine · completed · Breast Cancer · principal investigator
• Ph1/Ph2
  NCT00368875 · Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer

  National Cancer Institute (NCI) · completed · Male Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer · principal investigator
• Ph2
  NCT00049036 · Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

  National Cancer Institute (NCI) · completed · AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Peripheral/Systemic Lymphoma · principal investigator
• Ph2
  NCT00049114 · Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer

  National Cancer Institute (NCI) · completed · Inflammatory Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:07 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Consortium for Advancing Management and Prevention of Cancer in People with HIV
  UM1CA121947 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2020 to 2026 · $260,987 awarded in 2026
  Same name and institution; not confirmed by an ID
• Clinical Protocol & Data Management (CPDM)
  P30CA013330 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · fiscal years 2007 to 2021 · $175,117 awarded in 2021
  Grant number is on one of their registry trials
• MINORITY-BASED COMMUNITY ONCOLOGY PROGRAM
  UG1CA189859 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · fiscal years 2014 to 2019 · $753,649 awarded in 2019
  Same name and institution; not confirmed by an ID
• EASTERN COOPERATIVE ONCOLOGY GROUP
  U10CA014958 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · fiscal years 2002 to 2013 · $144,167 awarded in 2013
  Same name and institution; not confirmed by an ID
• Early Therapeutics Development with Phase II Emphasis
  N01CM62204- · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · fiscal years 2007 to 2011 · $472,963 awarded in 2011
  Grant number is on one of their registry trials
• EARLY THERAPEUTICS DEVELOPMENT WITH PHASE II EMPHASIS-261622004
  N01CM622004 · NCI · MONTEFIORE MEDICAL CENTER /INC · fiscal years 2006
  Same name and institution; not confirmed by an ID
• AIDS MALIGNANCY CONSORTIUM
  U01CA083038 · NCI · MONTEFIORE MEDICAL CENTER (BRONX, NY) · fiscal years 1999 to 2005 · $86,250 awarded in 2005
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• TARGETED INTERVENTION OF BREAST ONCOGENIC PATHWAYS
  R01CA098473 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SAID M SEBTI · fiscal years 2003 to 2014
  Named on NCT01697293
• AMC OPERATIONS CENTER
  U01CA070019 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Jeannette Y. Lee · fiscal years 1995 to 2005
  Named on NCT00049036